Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aridis Pharmaceuticals, Inc.ARDS · Entity 89417 | Director | December 05, 2022 | December 07, 2022 |
| CervoMed Inc.DFFN · Entity 7338 | Director | June 14, 2018 | June 18, 2018 |
| Elicio Therapeutics, Inc.ELTX · Entity 299 | Director | August 31, 2026 | September 02, 2026 |
| LB PHARMACEUTICALS INCLBRX · Entity 4678 | Director | June 03, 2026 | June 05, 2026 |
| Sigilon Therapeutics, Inc.SGTX · Entity 11481 | Director | August 11, 2023 | August 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aridis Pharmaceuticals, Inc.
Report date December 05, 2022 · Filed December 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 10,000 |
Reported balance
After 2022-12-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-05 · Grant · Acquired 10,000 · Balance 10,000 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: 5,000 shares of Common Stock will vest on June 5, 2023 and 5,000 will vest on 12/5/2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: 5,000 shares of Common Stock will vest on June 5, 2023 and 5,000 will vest on 12/5/2023.
CervoMed Inc.
Report date June 14, 2018 · Filed June 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2028-06-14 | Direct | 40,000 |
Reported balance
After 2018-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-14 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares underlying the options vest in 12 equal (or as nearly equal as possible) monthly installments over a one-year period beginning on the grant date, provided that the final tranche will vest on the day immediately prior to the subsequent annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the options vest in 12 equal (or as nearly equal as possible) monthly installments over a one-year period beginning on the grant date, provided that the final tranche will vest on the day immediately prior to the subsequent annual meeting.
Elicio Therapeutics, Inc.
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2036-08-31 | Direct | 21,750 |
Reported balance
After 2026-08-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 21,750 · Balance 21,750 F1: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.
LB PHARMACEUTICALS INC
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.95 · Expires 2036-06-02 | Direct | 10,000 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 10,000 · Balance 10,000 F1: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
Sigilon Therapeutics, Inc.
Report date August 11, 2023 · Filed August 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.28 · Expires 2033-05-18 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 683 · Balance 0 F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.92 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 683 · Balance 0 F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.41 · Expires 2026-07-13 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-11 · Disposition to issuer · Disposed 3,754 · Balance 0 F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.
F2: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 20:03 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 21,750 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001187308-26-000004 · wk-form4_1788379399.xml · derivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,750 Underlying: Common Stock · 21,750 shares Expires 2036-08-31 F1 · derivative.exercise_date: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 22:04 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $27.95 | $0.00 |
DisclosureSEC source: 0001187308-26-000002 · form4-06052026_100631.xml · derivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-06-02 F1 · derivative.exercise_date: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantStock Option (Right to Buy) · Derivative | 22,449 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001415889-25-024449 · form4-09122025_060913.xml · derivative · entry 7 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,449 Underlying: Common Stock · 22,449 shares Expires 2035-09-09 F4 · derivative.exercise_date: The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantStock Option (Right to Buy) · Derivative | 10,757 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001415889-25-024449 · form4-09122025_060913.xml · derivative · entry 6 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,757 Underlying: Common Stock · 10,757 shares Expires 2034-03-03 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on March 4, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,757 | Not disclosed Strike: $41.84 | Not disclosed |
DisclosureSEC source: 0001415889-25-024449 · form4-09122025_060913.xml · derivative · entry 5 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,757 shares Expires 2034-03-03 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on March 4, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantStock Option (Right to Buy) · Derivative | 717 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001415889-25-024449 · form4-09122025_060913.xml · derivative · entry 4 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 717 Underlying: Common Stock · 717 shares Expires 2030-08-24 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | Disposition to issuerStock Option (Right to Buy) · Derivative | 717 | Not disclosed Strike: $69.72 | Not disclosed |
DisclosureSEC source: 0001415889-25-024449 · form4-09122025_060913.xml · derivative · entry 3 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 717 shares Expires 2030-08-24 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantStock Option (Right to Buy) · Derivative | 1,792 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001415889-25-024449 · form4-09122025_060913.xml · derivative · entry 2 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,792 Underlying: Common Stock · 1,792 shares Expires 2028-06-26 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,792 | Not disclosed Strike: $69.72 | Not disclosed |
DisclosureSEC source: 0001415889-25-024449 · form4-09122025_060913.xml · derivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,792 shares Expires 2028-06-26 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 19, 2025 Filed May 20, 2025 20:06 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001601485-25-000085 · wk-form4_1747771551.xml · derivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,900 Underlying: Common Stock · 7,900 shares Expires 2035-05-19 F1 · shares: The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 12:34 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 4,100 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001601485-24-000093 · wk-form4_1732538054.xml · derivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,100 Underlying: Common Stock · 4,100 shares Expires 2034-11-21 F1 · shares: The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 22:05 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (right to buy) · Derivative | 4,100 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001140361-23-060233 · form4.xml · derivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,100 Underlying: Common Stock · 4,100 shares Expires 2033-12-28 F1 · shares: The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 20:10 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,754 | $7.51 Strike: $7.41 | $28,192.54 |
DisclosureSEC source: 0001415889-23-012131 · form4-08112023_040811.xml · derivative · entry 3 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,754 shares Expires 2026-07-13 F1 · derivative.exercise_price: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2 · price: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 20:10 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | Disposition to issuerStock Option (Right to Buy) · Derivative | 683 | $5.00 Strike: $9.92 | $3,413.91 |
DisclosureSEC source: 0001415889-23-012131 · form4-08112023_040811.xml · derivative · entry 2 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 683 shares Expires 2032-05-25 F1 · derivative.exercise_price: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2 · price: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 20:10 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | Disposition to issuerStock Option (Right to Buy) · Derivative | 683 | $6.64 Strike: $8.28 | $4,537.78 |
DisclosureSEC source: 0001415889-23-012131 · form4-08112023_040811.xml · derivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 683 shares Expires 2033-05-18 F1 · derivative.exercise_price: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split. F2 · price: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time. Read SEC document |
| May 19, 2023 Filed May 22, 2023 20:20 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001415889-23-008498 · form4-05222023_040520.xml · derivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2033-05-18 F1 · derivative.exercise_date: The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 19, 2024 Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 14:01 UTC | Aridis Pharmaceuticals, Inc. ARDS · Entity 89417 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-034686 · ownership.xml · derivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: 5,000 shares of Common Stock will vest on June 5, 2023 and 5,000 will vest on 12/5/2023. F2 · derivative.expiration_date: 5,000 shares of Common Stock will vest on June 5, 2023 and 5,000 will vest on 12/5/2023. Read SEC document |
| May 26, 2022 Filed May 27, 2022 21:00 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001415889-22-005829 · form4-05272022_050530.xml · derivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2032-05-25 F1 · derivative.exercise_date: The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 26, 2023. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 22:51 UTC | Aridis Pharmaceuticals, Inc. ARDS · Entity 89417 | GrantStock Options · Derivative | 7,000 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001104659-21-123286 · tm2129291-5_4seq1.xml · derivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,791 Underlying: Common Stock · 7,000 shares Expires 2031-10-04 F1 · derivative.exercise_date: The stock options vest in equal installments over 12 months, beginning on October 4, 2021. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:16 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,750 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001415889-21-003398 · form4-07022021_040740.xml · derivative · entry 3 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,805 Underlying: Common Stock · 6,750 shares Expires 2026-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on July 14, 2017, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:16 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | SaleCommon Stock | 6,750 | $10.36 | $69,930.00 |
DisclosureSEC source: 0001415889-21-003398 · form4-07022021_040740.xml · nonDerivative · entry 2 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.17 to $10.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:16 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | Exercise / conversionCommon Stock | 6,750 | $0.57 | $3,847.50 |
DisclosureSEC source: 0001415889-21-003398 · form4-07022021_040740.xml · nonDerivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 11:15 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $9.97 Strike: $9.97 | $88,613.36 |
DisclosureSEC source: 0001415889-21-003240 · form4-06282021_070612.xml · derivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2031-06-23 F1 · derivative.exercise_date: The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on June 24, 2022. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 22:49 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001104659-20-132939 · tm2037869-4_4seq1.xml · derivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2030-12-02 F1 · derivative.exercise_date: The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on the earlier of July 14, 2021 or the Company's next annual meeting of stockholders. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 23:27 UTC | Aridis Pharmaceuticals, Inc. ARDS · Entity 89417 | GrantStock Options · Derivative | 35,000 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0001104659-19-045979 · a4.xml · derivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,791 Underlying: Common Stock · 35,000 shares Expires 2029-08-13 F1 · derivative.exercise_date: The shares underlying this stock option vest in equal monthly installments over the 36 months following the date of grant. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:36 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001437749-18-012012 · rdgdoc.xml · derivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: The shares underlying the options vest in 12 equal (or as nearly equal as possible) monthly installments over a one-year period beginning on the grant date, provided that the final tranche will vest on the day immediately prior to the subsequent annual meeting. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:01 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001437749-18-000259 · rdgdoc.xml · derivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-01-02 F1 · derivative.exercise_date: The shares underlying the options vest in 12 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a one-year period beginning on January 31, 2018. Read SEC document |
| June 29, 2017 Filed Jul 13, 2017 19:48 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 52,057 | $0.00 Strike: $2.31 | $0.00 |
DisclosureSEC source: 0001437749-17-012576 · rdgdoc.xml · derivative · entry 1 RUFFOLO ROBERT R · CIK 0001187308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,057 Underlying: Common Stock · 52,057 shares Expires 2027-06-29 F1 · derivative.exercise_date: The shares underlying the options vest in equal parts on the first three anniversaries of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.